跳至主要内容
临床试验/JPRN-UMIN000020868
JPRN-UMIN000020868已完成2 期

Continuous regional arterial infusion (CRAI) versus venous infusion of Nafamostat mesilate for severe acute pancreatitis: a multicenter, open-label, randomized controlled trial. - A randomized controlled trial to evaluate CRAI of Nafamostat mesilate for severe acute pancreatitis (CRAI-SAP study)

Tohoku University Hospital, Division of Gastroenterology0 个研究点目标入组 40 人开始时间: 2016年2月3日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 79years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Previous CRAI therapy for the same disease. 2. Previous therapy using Nafamostat mesilate >39mg/kg/day, Gabexate mesilate >39mg/kg/day or Ulinastatin >300,000U/day for the same disease. 3. Unclear the starting time of severe abdominal pain. 4. Patient with concurrent pancreatic cancer. 5. History of the pancreas resection. 6. eGFR<30mL/min/1.73m2. 7. Serous K>5.5mEq/L. 8. Pregnancy. 9. Allergy to iodine contrast medium. 10. Contraindication for angiography. 11. Allergy to Nafamostat mesilate. 12. Untolerable quality of CT image. 13. Serious underlying disease.

研究者

发起方
Tohoku University Hospital, Division of Gastroenterology

相似试验

Continuous regional arterial infusion (CRAI) versus... | 临床试验